Cargando…

Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?

Introduction: Nusinersen is a recent promising therapy approved for the treatment of spinal muscular atrophy (SMA), a rare disease characterized by the degeneration of alpha motor neurons (αMN) in the spinal cord (SC) leading to progressive muscle atrophy and dysfunction. Muscle and cervical SC quan...

Descripción completa

Detalles Bibliográficos
Autores principales: Savini, Giovanni, Asteggiano, Carlo, Paoletti, Matteo, Parravicini, Stefano, Pezzotti, Elena, Solazzo, Francesca, Muzic, Shaun I., Santini, Francesco, Deligianni, Xeni, Gardani, Alice, Germani, Giancarlo, Farina, Lisa M., Bergsland, Niels, Gandini Wheeler-Kingshott, Claudia A. M., Berardinelli, Angela, Bastianello, Stefano, Pichiecchio, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039452/
https://www.ncbi.nlm.nih.gov/pubmed/33854470
http://dx.doi.org/10.3389/fneur.2021.613834
_version_ 1783677593245974528
author Savini, Giovanni
Asteggiano, Carlo
Paoletti, Matteo
Parravicini, Stefano
Pezzotti, Elena
Solazzo, Francesca
Muzic, Shaun I.
Santini, Francesco
Deligianni, Xeni
Gardani, Alice
Germani, Giancarlo
Farina, Lisa M.
Bergsland, Niels
Gandini Wheeler-Kingshott, Claudia A. M.
Berardinelli, Angela
Bastianello, Stefano
Pichiecchio, Anna
author_facet Savini, Giovanni
Asteggiano, Carlo
Paoletti, Matteo
Parravicini, Stefano
Pezzotti, Elena
Solazzo, Francesca
Muzic, Shaun I.
Santini, Francesco
Deligianni, Xeni
Gardani, Alice
Germani, Giancarlo
Farina, Lisa M.
Bergsland, Niels
Gandini Wheeler-Kingshott, Claudia A. M.
Berardinelli, Angela
Bastianello, Stefano
Pichiecchio, Anna
author_sort Savini, Giovanni
collection PubMed
description Introduction: Nusinersen is a recent promising therapy approved for the treatment of spinal muscular atrophy (SMA), a rare disease characterized by the degeneration of alpha motor neurons (αMN) in the spinal cord (SC) leading to progressive muscle atrophy and dysfunction. Muscle and cervical SC quantitative magnetic resonance imaging (qMRI) has never been used to monitor drug treatment in SMA. The aim of this pilot study is to investigate whether qMRI can provide useful biomarkers for monitoring treatment efficacy in SMA. Methods: Three adult SMA 3a patients under treatment with nusinersen underwent longitudinal clinical and qMRI examinations every 4 months from baseline to 21-month follow-up. The qMRI protocol aimed to quantify thigh muscle fat fraction (FF) and water-T2 (w-T2) and to characterize SC volumes and microstructure. Eleven healthy controls underwent the same SC protocol (single time point). We evaluated clinical and imaging outcomes of SMA patients longitudinally and compared SC data between groups transversally. Results: Patient motor function was stable, with only Patient 2 showing moderate improvements. Average muscle FF was already high at baseline (50%) and progressed over time (57%). w-T2 was also slightly higher than previously published data at baseline and slightly decreased over time. Cross-sectional area of the whole SC, gray matter (GM), and ventral horns (VHs) of Patients 1 and 3 were reduced compared to controls and remained stable over time, while GM and VHs areas of Patient 2 slightly increased. We found altered diffusion and magnetization transfer parameters in SC structures of SMA patients compared to controls, thus suggesting changes in tissue microstructure and myelin content. Conclusion: In this pilot study, we found a progression of FF in thigh muscles of SMA 3a patients during nusinersen therapy and a concurrent slight reduction of w-T2 over time. The SC qMRI analysis confirmed previous imaging and histopathological studies suggesting degeneration of αMN of the VHs, resulting in GM atrophy and demyelination. Our longitudinal data suggest that qMRI could represent a feasible technique for capturing microstructural changes induced by SMA in vivo and a candidate methodology for monitoring the effects of treatment, once replicated on a larger cohort.
format Online
Article
Text
id pubmed-8039452
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80394522021-04-13 Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment? Savini, Giovanni Asteggiano, Carlo Paoletti, Matteo Parravicini, Stefano Pezzotti, Elena Solazzo, Francesca Muzic, Shaun I. Santini, Francesco Deligianni, Xeni Gardani, Alice Germani, Giancarlo Farina, Lisa M. Bergsland, Niels Gandini Wheeler-Kingshott, Claudia A. M. Berardinelli, Angela Bastianello, Stefano Pichiecchio, Anna Front Neurol Neurology Introduction: Nusinersen is a recent promising therapy approved for the treatment of spinal muscular atrophy (SMA), a rare disease characterized by the degeneration of alpha motor neurons (αMN) in the spinal cord (SC) leading to progressive muscle atrophy and dysfunction. Muscle and cervical SC quantitative magnetic resonance imaging (qMRI) has never been used to monitor drug treatment in SMA. The aim of this pilot study is to investigate whether qMRI can provide useful biomarkers for monitoring treatment efficacy in SMA. Methods: Three adult SMA 3a patients under treatment with nusinersen underwent longitudinal clinical and qMRI examinations every 4 months from baseline to 21-month follow-up. The qMRI protocol aimed to quantify thigh muscle fat fraction (FF) and water-T2 (w-T2) and to characterize SC volumes and microstructure. Eleven healthy controls underwent the same SC protocol (single time point). We evaluated clinical and imaging outcomes of SMA patients longitudinally and compared SC data between groups transversally. Results: Patient motor function was stable, with only Patient 2 showing moderate improvements. Average muscle FF was already high at baseline (50%) and progressed over time (57%). w-T2 was also slightly higher than previously published data at baseline and slightly decreased over time. Cross-sectional area of the whole SC, gray matter (GM), and ventral horns (VHs) of Patients 1 and 3 were reduced compared to controls and remained stable over time, while GM and VHs areas of Patient 2 slightly increased. We found altered diffusion and magnetization transfer parameters in SC structures of SMA patients compared to controls, thus suggesting changes in tissue microstructure and myelin content. Conclusion: In this pilot study, we found a progression of FF in thigh muscles of SMA 3a patients during nusinersen therapy and a concurrent slight reduction of w-T2 over time. The SC qMRI analysis confirmed previous imaging and histopathological studies suggesting degeneration of αMN of the VHs, resulting in GM atrophy and demyelination. Our longitudinal data suggest that qMRI could represent a feasible technique for capturing microstructural changes induced by SMA in vivo and a candidate methodology for monitoring the effects of treatment, once replicated on a larger cohort. Frontiers Media S.A. 2021-03-29 /pmc/articles/PMC8039452/ /pubmed/33854470 http://dx.doi.org/10.3389/fneur.2021.613834 Text en Copyright © 2021 Savini, Asteggiano, Paoletti, Parravicini, Pezzotti, Solazzo, Muzic, Santini, Deligianni, Gardani, Germani, Farina, Bergsland, Gandini Wheeler-Kingshott, Berardinelli, Bastianello and Pichiecchio. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Savini, Giovanni
Asteggiano, Carlo
Paoletti, Matteo
Parravicini, Stefano
Pezzotti, Elena
Solazzo, Francesca
Muzic, Shaun I.
Santini, Francesco
Deligianni, Xeni
Gardani, Alice
Germani, Giancarlo
Farina, Lisa M.
Bergsland, Niels
Gandini Wheeler-Kingshott, Claudia A. M.
Berardinelli, Angela
Bastianello, Stefano
Pichiecchio, Anna
Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?
title Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?
title_full Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?
title_fullStr Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?
title_full_unstemmed Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?
title_short Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?
title_sort pilot study on quantitative cervical cord and muscular mri in spinal muscular atrophy: promising biomarkers of disease evolution and treatment?
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039452/
https://www.ncbi.nlm.nih.gov/pubmed/33854470
http://dx.doi.org/10.3389/fneur.2021.613834
work_keys_str_mv AT savinigiovanni pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT asteggianocarlo pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT paolettimatteo pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT parravicinistefano pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT pezzottielena pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT solazzofrancesca pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT muzicshauni pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT santinifrancesco pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT deligiannixeni pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT gardanialice pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT germanigiancarlo pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT farinalisam pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT bergslandniels pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT gandiniwheelerkingshottclaudiaam pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT berardinelliangela pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT bastianellostefano pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment
AT pichiecchioanna pilotstudyonquantitativecervicalcordandmuscularmriinspinalmuscularatrophypromisingbiomarkersofdiseaseevolutionandtreatment